ETF Market Flows: iShares NASDAQ Biotechnology Index (ETF) Registered $-129.04M Redemptions Because Of -1.49% AUM Decrease

ETF Market Flows: iShares NASDAQ Biotechnology Index (ETF) Registered $ 129.04M Redemptions Because Of  1.49% AUM Decrease

Today were reported iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB)‘s daily net flows. The ETF registered $-129.04M asset outflows for -1.49% decrease, reaching $8559.42M after yestarday’s trading session. The chart of iShares NASDAQ Biotechnology Index (ETF) shows negative short-term setup. In the net flows calculation is not included the performance of the etf but only share redemptions (outflows) and share purchases (inflows). Net outflows leads to less cash for managers to invest, which theoretically decreases demand for the etf’s holdings. The ETF increased 0.88% or $2.48 on November 23, hitting $283.84. About 1.88 million shares traded hands. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has declined 1.60% since April 22, 2016 and is downtrending. It has underperformed by 7.00% the S&P500.

The ETF’s YTD performance is -24.02%, the 1 year is -21.01% and the 3 year is 7.85%.

The ETF’s average P/E ratio is 18.14, the price to book is 3.26, the price to sales is 4.65 and the price to cashflow is 9.14. iShares NASDAQ Biotechnology Index (ETF) is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001. The fund’s top holdings are: Celgene Corporation for 8.58% of assets, Gilead Sciences Inc. for 8.42%, Biogen Inc. for 8.22%, Amgen Inc. for 7.44%, Regeneron Pharmaceuticals Inc. for 6.90%, Alexion Pharmaceuticals Inc. for 4.65%, Mylan N.V. for 3.86%, Illumina Inc. for 3.62%, Vertex Pharmaceuticals Incorpor for 3.60%, Incyte Corporation for 3.24%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0% yield.

More notable recent iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) news were published by: Investorplace.com which released: “Is the IShares Nasdaq Biotechnology Index (ETF) (IBB) Verging on a Breakout?” on November 23, 2016, also Fool.com with their article: “2 Reasons Why the iShares NASDAQ Biotechnology Index (ETF) Tumbled 11% in October” published on November 07, 2016, Investorplace.com published: “3 Big Stock Charts: iShares NASDAQ Biotechnology Index (ETF) (IBB …” on November 09, 2016. More interesting news about iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) were released by: Investorplace.com and their article: “The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Critical Level” published on October 17, 2016 as well as Profitconfidential.com‘s news article titled: “iShares NASDAQ Biotechnology ETF: Has IBB Stock Finally Bottomed?” with publication date: July 17, 2016.

IBB Company Profile

iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, and which also meet other eligibility criteria. The Index is one of the eight sub-indices of the NASDAQ Composite, which measures all common stocks listed on The NASDAQ Stock Market, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment